Company Announcement, Helsinki, 30 December 2025 at 10 AM (EET)
Nexstim Plc’s Financial Information and Annual General Meeting in 2026
Nexstim Plc ("Nexstim" or "Company") announces the following schedule for its financial information releases and Annual General Meeting in 2026:
- The 2025 Financial Statements and Half-Yearly Report July−December 2025 (H2) will be released on Thursday February 26, 2026.
- Half-Yearly Report January-June 2026 (H1) will be released on Friday August 14, 2026.
Nexstim’s Annual Report 2025 will be published and available on the Company’s website on Thursday March 5, 2026.
The Annual General Meeting is tentatively scheduled to be held on Monday March 30, 2026, at 10:00 am.
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com